The latest price target for Capricor Therapeutics (NASDAQ: CAPR) was reported by Ladenburg Thalmann on October 26, 2022. The analyst firm set a price target for $15.00 expecting CAPR to rise to within 12 months (a possible 161.78% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Capricor Therapeutics (NASDAQ: CAPR) was provided by Ladenburg Thalmann, and Capricor Therapeutics initiated their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Capricor Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Capricor Therapeutics was filed on October 26, 2022 so you should expect the next rating to be made available sometime around October 26, 2023.

While ratings are subjective and will change, the latest Capricor Therapeutics (CAPR) rating was a initiated with a price target of $0.00 to $15.00. The current price Capricor Therapeutics (CAPR) is trading at is $5.73, which is within the analyst's predicted range.